Role of Alcohol Metabolism in Non-Alcoholic Steatohepatitis

Susan S. Baker¹, Robert D. Baker¹, Wensheng Liu¹, Norma J. Nowak²,³, Lixin Zhu¹

¹ Digestive Diseases and Nutrition Center, Department of Pediatrics, The State University of New York, Buffalo, New York, United States of America, ² Department of Biochemistry and the New York State Center of Excellence in Bioinformatics and Life Sciences, The State University of New York at Buffalo, Buffalo, New York, United States of America, ³ Microarray and Genomics Facility, Roswell Park Cancer Institute, Buffalo, New York, United States of America

Abstract

**Background:** Non-alcoholic steatohepatitis (NASH) is a serious form of non-alcoholic fatty liver disease (NAFLD), associated with obesity and insulin resistance. Previous studies suggested that intestinal bacteria produced more alcohol in obese mice than lean animals.

**Methodology/Principal Findings:** To investigate whether alcohol is involved in the pathogenesis of NASH, the expression of inflammation, fibrosis and alcohol metabolism related genes in the liver tissues of NASH patients and normal controls (NCs) were examined by microarray (NASH, n = 7; NC, n = 4) and quantitative real-time PCR (NASH, n = 6; NC, n = 6). Genes related to liver inflammation and fibrosis were found to be elevated in NASH livers compared to normal livers. The most striking finding is the increased gene transcription of alcohol dehydrogenase (ADH) genes, genes for catalase and cytochrome P450 2E1, and aldehyde dehydrogenase genes. Immunoblot analysis confirmed the increased expression of ADH1 and ADH4 in NASH livers (NASH, n = 9; NC, n = 4).

**Conclusions/Significance:** The augmented activity of all the available genes of the pathways for alcohol catabolism suggest that 1) alcohol concentration was elevated in the circulation of NASH patients; 2) there was a high priority for the NASH livers to scavenge alcohol from the circulation. Our data is the first human evidence that suggests alcohol may contribute to the development of NAFLD.

Introduction

Non-alcoholic steatohepatitis (NASH) is a serious form of non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis associated with evidence of inflammation and variable degrees of fibrosis [1]. The prevalence of NASH is increasing with the ever-growing problem of obesity in the general population. Up to 20% of the population may have fatty liver, and up to 3% may have NASH as estimated in 2004 [2].

According to the current “two-hit” hypothesis, NASH patients first develop fatty liver before a second hit initiates inflammation in the liver [3]. Studies with NASH patients and various animal models in the last decade have revealed insights into liver fat infiltration, damage, inflammation and fibrosis. Insulin resistance (IR) seems to be a major reason for fat deposition in liver by way of uncontrolled lipolysis in adipose tissue leading to increased levels of circulating free fatty acids [4]. Measurement with stable isotopes in NAFLD patients indicated that free fatty acids are the major source for fat accumulation in liver. De novo lipogenesis and dietary fatty acids are also significant sources of fat [5]. Other studies suggested that insufficient fatty acid utilization could also cause fat deposition in hepatocytes. Peroxisome proliferator-activated receptors are transcriptional factors regulating lipid metabolism in liver and therefore believed to play a central role in hepatic fat accumulation [6]. Lipotoxicity may cause mitochondrial dysfunction and subsequent liver damage and trigger inflammation [7]. Oxidative stress is possibly a potent thrust in this process and in subsequent activation of hepatic stellate cells [8].

Despite these efforts, the exact mechanism of the development of NASH is unclear. And it remains a puzzle that NASH and alcoholic steatohepatitis share many histological features [9]. Both NASH and alcoholic steatohepatitis patients exhibit macrovesicular and microvesicular fat in hepatocytes. The number and size of Mallory bodies, and the pattern of pericellular fibrosis are also indistinguishable between two disease groups. Previous studies suggested that intestinal bacteria produced more alcohol in obese mice than lean animals [10]. Therefore, we hypothesize that alcohol is involved in the pathogenesis of NASH.

In this report, gene expression in NASH livers was examined by a whole-genome DNA microarray and quantitative real-time PCR (qRT-PCR). We found that all the available genes of the pathways for alcohol catabolism exhibited elevated expression levels in NASH livers, among which the elevated protein levels of ADH1
and ADH4 in NASH livers were confirmed by Western blot analysis. Our results suggest a key role for intestinal alcohol in the pathogenesis of NASH.

Methods

Patients

The human studies have been approved by the Institutional Review Board (IRB) of the State University of New York at Buffalo. Only children and adolescents were included in this study to ensure that our patients were not sustained alcohol users. All NASH patients included in this study (Table 1) exhibited significant insulin resistance (IR). IR was calculated based on the “homeostasis model assessment (HOMA)” method [11]. Liver biopsies were obtained, with prior written consent, from parents of patients suspected of having NASH as part of regular medical care. Patients from 7 to 18 years of age signed an assent to the research. Diagnosis of NASH was based on hepatic fat infiltration, inflammation and fibrosis as revealed by liver biopsy, following Kleiner’s criteria [12].

For non-steatosis controls, total RNA was purchased from Admet Technologies (Durham, NC). These samples were derived from liver grafts of normal controls with normal body mass index (Table 1). The ages of these normal controls were similar to our NASH patients. No liver diseases were diagnosed with these normal controls. The healthy status of these livers was ascertained by the lower transcription levels of marker genes for inflammation and fibrosis, as detailed in the Results section. The non-NASH controls used in Western blot analysis were liver biopsies from patients with hepatitis C, autoimmune hepatitis, gall stones or cystic fibrosis, respectively. They were free from steatosis.

Table 1: Characteristics of study groups.

|               | Microarray | Real-time PCR | Western blot |
|---------------|------------|---------------|--------------|
|               | NASH       | Normal control| NASH         | Normal control| NASH | Non-NASH control |
| Sex (F : M)   | F2 : M5    | F1 : M3       | F2 : M3      | F2 : M4       | F4 : M5 | F3 : M1          |
| Age (years)   | 9–16       | 1–19          | 9–14         | 1–9           | 11–18  | 4–12             |
| Body Mass Index | 35.0±2.9†  | 19.1±1.6†     | 38.4±5.9†    | 16.5±0.8†     | 32.7±1.6§ | 20.6±2.9§        |
| Fasting Insulin (mU/ml) | 27.0±2.2   | NA            | 31.2±2.3     | NA            | 20.7±5.1 | <2               |
| Fasting glucose (mmol/L) | 5.0±0.2    | NA            | 5.1±0.3      | NA            | 5.7±0.4  | 4.7±0.2          |
| IR (HOMA)††  | 6.0±0.5    | NA            | 7.0±0.5      | NA            | 5.7±1.7  | <1               |

1 Normal healthy liver intended for transplantation, no liver disease reported.

2 Liver biopsies from patients with hepatitis C, autoimmune hepatitis, gall stones or cystic fibrosis, respectively. They were free from steatosis.

3 Patients are all above 95 percentile of the population.

*Normal controls are all below 80 percentile of the population.

† IR (HOMA) for healthy subjects is around 1.

NA: Not available.

doi:10.1371/journal.pone.0009570.t001

Table 2. Primer pairs for real-time quantitative PCR analysis.

| Symbol | Description                   | Sequence                                      |
|--------|-------------------------------|-----------------------------------------------|
| GAPD   | glyceraldehyde-3-phosphate dehydrogenase | AGCCCTCAAGGCTGATTCACTGAGCAAT | (Forward) |
|        |                               | ATGGAGCTGTCATGATCATTTC | (Reverse) |
| CXCL10 | chemokine (C-X-C motif) ligand 10 | TTCTGGAAGCCTATTTTGT | (Forward) |
|        |                               | ATGCCCTTGGATCTTGGATT | (Reverse) |
| ADH1C  | alcohol dehydrogenase 1C (class I) | GCGCTGACCATGATGGCT | (Forward) |
|        |                               | GAGGATCTCACCTACATGCA | (Reverse) |
| ADH4   | alcohol dehydrogenase 4 (class II) | CTGAAGCTGAAGGACGCC | (Forward) |
|        |                               | GCCGATTTCATAGCCTGCC | (Reverse) |
| ADH6   | alcohol dehydrogenase 6 (class V) | CAATACGGGAGATGCACT CCC | (Forward) |
|        |                               | GCCTCCTGTCAGCTTCAACC | (Reverse) |
| ALDH2  | aldehyde dehydrogenase 2       | TGGTACTTACCTACGGCCC | (Forward) |
|        |                               | GCCTCCTGAAACACCTCCCTCAT | (Reverse) |
| ALDH8A1| aldehyde dehydrogenase 8 family, member A1 | TGGAGCTGCTGGCTCTGG | (Forward) |
|        |                               | CTGGGCTTGGCTATACAGG | (Reverse) |
| TLR4   | toll-like receptor 4           | AATCCCTGAGGATCTTGAG | (Forward) |
|        |                               | CCCATCTTCAATGCTGG | (Reverse) |

doi:10.1371/journal.pone.0009570.t002
RNA Extraction and Microarray Hybridization

Liver biopsies were stored in RNAlater before total RNA was extracted with RNeasy and treated with RNase-free DNase I set (Qiagen, Valencia, CA). RNA samples obtained from Admet were also treated with RNase free DNase before downstream experiments. Quality of the RNA samples was assured with Bioanalyzer (Agilent Technologies) before downstream biotin labeling and hybridization to the CodeLink Human Whole Genome Bioarray (GE Health care-Amersham Biosciences, Piscataway, NJ) following the manufacturer’s manual. The original microarray data have been uploaded to Gene Expression Omnibus (GEO) website: http://www.ncbi.nlm.nih.gov/geo/index.cgi. All data is MIAME compliant. The accession numbers for NASH control datasets: GSM435828, GSM435833 to GSM435835. Liver datasets are GSM435821 to GSM435827, and for normal tissues: GSM435836 to GSM435848.

Quantitative RT-PCR

Specific primers (Table 2) were designed with the assistance of Primer 3 [13]. Complementary DNA was synthesized from 0.8 μg of total RNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA), using Sybergreen iQ™ SYBR® Green Supermix; Bio-Rad Laboratories, Hercules, CA) for real-time monitoring of the PCR. GAPD RNA level were tested in parallel with the genes of interest. The presence of a single specific PCR product was verified by melting curve analysis and confirmed on agarose gels.

Threshold cycles (Ct) for each sample were determined by Bio-rad iQ5 optical system software (Bio-Rad Laboratories). The concentration of mRNA ([mRNA]) is given by the following equation: [mRNA] = M/E^Ct, where constant M is an arbitrary threshold, E is the efficiency of PCR, Ct is the threshold cycle. All PCR reactions had efficiencies higher than 1.9, as determined experimentally with 4-times serial diluted samples. The relative mRNA concentration of each target gene was calculated as the mRNA concentration of target gene normalized against that of GAPD, as represented by the following equation:

\[
\frac{[\text{mRNA}]_{\text{target}}}{[\text{mRNA}]_{\text{GAPD}}} = E_{\text{GAPD}}^{\text{Ct}_{\text{GAPD}} - \text{Ct}_{\text{target}}}
\]

Western Blot Analysis

Liver biopsies stored in RNAlater were homogenized in PBS, and then boiled for 5 min in SDS-PAGE loading buffer. Samples were then analyzed with Western blot with anti-pi polypeptide ADH4 (1:1000), anti-hepatic triglyceride lipase (HTGL) (1:1000), anti-actin (1:2000), anti-cytochrome P450, family 3, subfamily A, polypeptide 1 (CYP3A5) (1:2000), anti-glutathione S-transferase A1 (GSTA1) (1:1000). Immunoblots were visualized using Enhanced Chemiluminescence (ECL) reagents (Pierce, Rockford, IL) and films.

Table 3. Comparison of the gene expressions between liver tissues and breast cancer tissues.

| GenBank Accession # | Gene Description | NASH Liver (n = 7) | Normal Liver (n = 4) | Breast Cancer (n = 4) | NASH Liver/Breast Cancer† |
|--------------------|------------------|-------------------|---------------------|----------------------|--------------------------|
| NM_000402.2        | glucose-6-phosphate dehydrogenase (G6PD) | 1.58 ± 0.10       | 1.53 ± 0.27         | 1.37 ± 0.64          | 1.16                     |
| NM_001101.2        | actin, beta (ACTB) | 18.19 ± 2.91      | 16.07 ± 4.88        | 20.38 ± 19.35        | 0.89                     |
| NM_000034.2        | aldolase A, fructose-bisphosphate (ALDOA) | 9.02 ± 1.63       | 19.02 ± 4.34        | 6.91 ± 6.18          | 1.30                     |
| NM_003379.3        | villin 2 (ezrin) (VIL2) | 1.78 ± 0.42       | 4.02 ± 1.28         | 1.38 ± 0.84          | 1.29                     |
| AL133626.1         | H2A histone family, member J | 1.66 ± 0.12       | 1.81 ± 0.22         | 1.88 ± 0.20          | 0.88                     |
| NM_002954.3        | ribosomal protein S27a (RPS27A) | 171.21 ± 46.00    | 184.38 ± 33.35      | 91.67 ± 61.77        | 1.87                     |
| NM_006951.2        | TAF5 RNA polymerase II binding protein-associated factor | 1.64 ± 0.24       | 1.04 ± 0.25         | 1.46 ± 0.20          | 1.13                     |
| NM_001190.1        | branched chain aminotransferase precursor (BCATm) | 1.32 ± 0.42       | 1.40 ± 0.64         | 1.44 ± 0.39          | 0.92                     |
| NM_000777.2        | cytochrome P450, family 3, subfamily A, polypeptide 1 (CYP3A5) | 4.91 ± 1.83       | 8.08 ± 3.40         | 0.00 ± 0.21          | 1017.97                  |
| NM_000401.1        | apolipoprotein C-III (APOC3) | 625.93 ± 126.08   | 312.83 ± 67.97      | 0.40 ± 0.00          | 1579.62                  |
| NM_001443.1        | fatty acid binding protein 1, liver (FABP1) | 605.55 ± 80.67    | 250.15 ± 51.55      | 0.42 ± 0.25          | 1458.34                  |
| NM_000039.1        | apolipoprotein A-I (APOA1) | 557.21 ± 58.12    | 306.33 ± 52.72      | 0.52 ± 0.16          | 1071.00                  |
| NM_006744.2        | retinol binding protein 4, plasma (RBPA4) | 606.95 ± 83.36    | 295.00 ± 43.11      | 0.68 ± 0.30          | 888.88                   |
| NM_145740.1        | glutathione S-transferase A1 (GSTA1) | 312.50 ± 33.64    | 25.17 ± 14.02       | 0.42 ± 0.22          | 742.18                   |
| NM_000667.2        | alcohol dehydrogenase 1A (class I), alpha polypeptide (ADH1A) | 470.96 ± 40.68    | 82.50 ± 34.30       | 0.64 ± 0.11          | 735.11                   |
| NM_000483.3        | apolipoprotein C-II (APOC2) | 501.93 ± 30.57    | 288.10 ± 49.95      | 1.20 ± 0.75          | 419.61                   |
| NM_000236.1        | hepatic triglyceride lipase (HTGL) | 289.35 ± 47.50    | 142.52 ± 10.06      | 0.76 ± 0.23          | 383.05                   |
| NM_000670.2        | alcohol dehydrogenase 4 (class II), pi polypeptide (ADH4) | 257.14 ± 38.38    | 6.53 ± 2.17         | 0.80 ± 0.44          | 323.14                   |
| NM_000041.1        | apolipoprotein E (APOE) | 353.83 ± 49.92    | 258.38 ± 53.30      | 1.81 ± 0.63          | 195.99                   |

†Microarray data for breast cancer were downloaded from PubMed, accession #: GSE6304.

Fold difference of gene expression levels (sample mean) between NASH liver tissues and breast cancer tissues.

Median normalized gene expression signal as detected by the CodeLink microarray. Sample mean ± standard error.

For all the liver specific genes listed, significant differences in gene expression were detected between liver tissues and breast cancer tissues (P < 0.05). doi:10.1371/journal.pone.0009570.t003
(4 μg total protein each) were separated on 10% SDS PAGE gels. After blotting onto nitrocellulose membranes, ADH1 (cat#: sc-137091, Santa Cruz Biotechnology Inc., CA), ADH4 (cat#: sc-134249, Santa Cruz Biotechnology Inc.) and β-actin (Clone C4, MP Biomedicals, LLC, Ohio) were probed on separate blots, as all these proteins are of similar sizes. The results were visualized using

### Table 4. Comparison of gene expressions between NASH livers and normal controls: house-keeping genes, inflammation and fibrosis related genes.

| Accession# | Gene Description                                      | NASH Liver (n = 7) | Normal Liver (n = 4) | NASH/Normal | P value |
|------------|-------------------------------------------------------|--------------------|----------------------|-------------|---------|
| NM_002121.4 | major histocompatibility complex, class II, DP beta 1 (HLA-DPB1) | 70.94 ± 8.30       | 3.49 ± 1.96          | 20.31       | 0.000   |
| NM_004120.2 | major histocompatibility complex, class II, DM alpha (HLA-DMA) | 24.91 ± 3.39       | 4.77 ± 1.41          | 5.22        | 0.001   |
| NM_002121.4 | major histocompatibility complex, class II, DP beta 1 (HLA-DPB1) | 15.86 ± 2.85       | 1.01 ± 0.28          | 15.64       | 0.002   |
| NM_002127.3 | HLA-G histocompatibility antigen, class I, G (HLA-G) | 27.88 ± 2.00       | 7.97 ± 0.71          | 3.50        | 0.000   |
| NM_019111.2 | major histocompatibility complex, class II, DR alpha (HLA-DRA) | 153.26 ± 18.42     | 15.67 ± 4.81         | 9.78        | 0.000   |
| NM_006951.2 | TAF5 RNA polymerase II, TATA box binding protein (TBP)-associated factor | 1.64 ± 0.24        | 1.04 ± 0.25          | 1.59        | 0.122   |
| NM_001190.1 | branched chain aminotransferase precursor (BCATm) | 1.32 ± 0.42        | 1.40 ± 0.64          | 0.94        | 0.922   |
| NM_000072.1 | CD36 antigen (collagen type I receptor, thrombospondin receptor) (CD36) | 16.55 ± 3.10       | 2.87 ± 1.63          | 5.76        | 0.004   |
| NM_005505.3 | CD36 antigen (collagen type I receptor, thrombospondin receptor)-like 1 (CD36L1) | 1.84 ± 0.41       | 0.76 ± 0.15          | 2.42        | 0.041   |
| NM_030582.2 | collagen, type XVIII, alpha 1 (COL18A1) | 29.30 ± 3.83       | 9.69 ± 2.14          | 3.02        | 0.002   |
| NM_004369.1 | RNA for type VI collagen alpha3 chain | 4.73 ± 0.79       | 1.41 ± 0.73          | 3.36        | 0.014   |
| NM_001918.2 | collagen, type VIII, alpha 1 (COL8A1) | 1.10 ± 0.10       | 0.28 ± 0.17          | 3.95        | 0.011   |
| NM_0015719.2 | collagen, type V, alpha 3 (COL5A3) | 0.98 ± 0.26       | 0.17 ± 0.05          | 5.73        | 0.019   |

*The gene expression levels (sample mean ± standard error) shown were median normalized.

**Fold difference of gene expression levels (sample mean) between NASH liver tissues and normal liver controls.

*Two tailed student t test.

DOI: 10.1371/journal.pone.0009570.004
the SuperSignal West Dura Extended Duration Substrate (Invitrogen) and recorded with an image reader LAS-1000 (Fujifilm).

**Statistical Analysis**

All analysis for statistically significant differences was performed with Student’s t test with a two-tailed distribution. P values smaller than 0.05 were considered significant.

**Results**

**The Integrity of the Microarray Datasets**

To compare the global gene expression profiles between NASH livers and normal livers, total RNA samples from both populations (NASH, n = 7; NC, n = 4) were analyzed on CodeLink Human Whole Genome Bioarray. To ascertain the quality of RNA used in microarray analysis, similar datasets of breast cancer tissue generated with the same CodeLink platform were downloaded (GEO accession numbers: GSM144855 to GSM144858) and compared with the liver microarray datasets. As represented by the housekeeping genes listed in Table 3 (upper part), the majority of the genes showed similar expression levels among NASH livers, normal livers and breast cancer tissues. In contrast, drastically elevated expression was detected in liver tissues for the liver-specific genes including apolipoproteins, fatty acid binding protein, hepatic triglyceride lipase, glutathione S-transferase, and alcohol dehydrogenase (Table 3, lower part).

**Elevated Expression of Inflammation and Fibrosis Related Genes in NASH Livers**

The expression levels of genes involved in the process of inflammation and fibrosis were of immediate attention, as the activities of these genes would provide an ultimate evaluation of the quality of the datasets. Listed in Table 4, most of the chosen housekeeping genes showed similar transcription levels between NASH livers and normal controls (Table 4, upper panel). In contrast, significant differences were observed for many genes known to be involved in inflammation (Table 4, middle panel). These include several members of the HLAs, C-X-C motif containing chemokines and members of the TNF receptor superfamily.

The NASH patients included in this study all had certain degrees of fibrosis. It was therefore of great interest to see if the NASH microarray dataset could characterize the disease status. The abnormal deposition of collagen is a structural basis of liver fibrosis. From the datasets, it was noted that several types of collagen and collagen receptor exhibited elevated transcription activity in NASH livers (Table 4, lower panel). The activation of stellate cells from their resting state to myofibroblasts was also suggested by the elevated transcription for genes specific for smooth muscle functions (data not shown).

To confirm the observations made with the microarray technique, cDNA was synthesized from liver RNA and subjected to qRT-PCR analysis (NASH, n = 6; NC, n = 6) with gene specific primer pairs for GAPD and CXCL10 (Table 2). CXCL10 was chosen because it was the most highly activated inflammatory gene based on the microarray datasets. The real-time PCR result (Figure 1) indicated that the transcription level of CXCL10 in NASH liver was 21.86 times of that in normal healthy liver (P = 0.003), which is consistent with the microarray data (in which, NASH/normal = 21.55).

Overall, the elevated transcription of inflammation and fibrosis related genes validated both the NASH and normal control samples for further investigation on the gene expression patterns of NASH livers.
in NASH livers than in normal livers (Figure 2, A, B and C). In NASH livers, the ADH1C transcription was 12.5 times that of normal livers. For ADH4 and ADH6, it was 30.89 and 9.81 times, respectively. Note that these numbers showed a similar pattern given by microarray data, in which NASH/normal = 4.08 (ADH1C), 39.40 (ADH4), and 10.30 (ADH6). Significantly higher transcriptional activities of ALDH2 and ALDH8A1 were also observed by qRT-PCR in NASH livers compared to normal livers (Figure 2, D and E), confirming the previously described microarray data.

NASH Liver Did Not Exhibit Elevated Gene Transcription for TLR4 and Related Genes

Studies with rodent models suggested that TLR4 mediated pathway is elevated in NASH liver[15,16]. From our microarray data, the gene transcription of TLR4 was slightly elevated in NASH patients (NASH/normal = 1.35, P<0.05). Yet the transcription of TLR4 related genes CD14, LBP and MD-2 were not elevated (Table 5, lower panel). In fact, a significant decrease in LBP transcription was detected with these patients (NASH/normal = 0.4,

Table 5. Comparison of gene expressions between NASH livers and normal controls: alcohol metabolism and TLR4 related genes.1

| GenBank Accession# | Gene Description | NASH Liver (n = 7) | Normal Liver (n = 4) | NASH/Normal1 | P value1 |
|--------------------|------------------|-------------------|---------------------|--------------|----------|
| NM_000667.2        | alcohol dehydrogenase 1A (class I), alpha polypeptide (ADH1A) | 470.96±0.68 | 82.50±34.30 | 5.71 | 0.000 |
| NM_000668.3        | alcohol dehydrogenase IB (class II), beta polypeptide (ADH1B) | 95.00±21.68 | 34.23±9.89 | 2.78 | 0.034 |
| NM_000669.2        | alcohol dehydrogenase 1C (class I), gamma polypeptide (ADH1C) | 76.58±16.72 | 18.75±5.60 | 4.08 | 0.013 |
| NM_000670.2        | alcohol dehydrogenase 4 (class II), pi polypeptide (ADH4) | 257.14±38.38 | 6.53±2.17 | 39.40 | 0.001 |
| NM_000671.2        | alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5) | 10.95±1.97 | 2.71±1.16 | 4.04 | 0.006 |
| NM_000672.2        | alcohol dehydrogenase 6 (class V) (ADH6) | 36.68±5.09 | 3.56±1.14 | 10.30 | 0.000 |
| NM_000673.2        | alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide (ADH7) | 0.34±0.08 | 0.01±0.11 | 26.96 | 0.053 |
| NM_000773.2        | cytochrome P450, family 2, subfamily E, polypeptide 1 (CYP2E1) | 423.85±42.84 | 194.97±50.22 | 2.17 | 0.010 |
| NM_000689.3        | alcohol dehydrogenase 1 family, member A1 (ALDH1A1) | 45.47±9.70 | 5.61±2.18 | 8.11 | 0.006 |
| NM_003888.2        | alcohol dehydrogenase 1 family, member A2 (ALDH1A2) | 0.70±0.13 | 0.27±0.09 | 2.57 | 0.023 |
| NM_000692.3        | alcohol dehydrogenase 1 family, member B1 (ALDH1B1) | 63.79±5.52 | 15.01±2.81 | 4.25 | 0.000 |
| NM_000690.2        | alcohol dehydrogenase 2 family (mitochondrial) (ALDH2) | 4.47±1.07 | 0.71±0.24 | 6.30 | 0.012 |
| NM_000695.2        | alcohol dehydrogenase 3 family, member B2 (ALDH3B2) | 0.37±0.10 | 0.24±0.09 | 1.55 | 0.354 |
| NM_003748.2        | alcohol dehydrogenase 4 family, member A1 (ALDH4A1) | 25.86±3.87 | 16.25±2.08 | 1.59 | 0.058 |
| NM_001080.3        | alcohol dehydrogenase 5 family, member A1 (ALDH5A1) | 3.79±0.41 | 1.31±0.45 | 2.89 | 0.004 |
| NM_000693.1        | alcohol dehydrogenase 6 mRNA, complete cds | 0.49±0.12 | 0.33±0.08 | 1.48 | 0.280 |
| NM_00694.1         | alcohol dehydrogenase ALDH7 | 8.17±0.52 | 3.26±0.21 | 2.51 | 0.000 |
| NM_002568.2        | alcohol dehydrogenase 8 family, member A1 (ALDH8A1) | 24.43±1.84 | 5.46±0.57 | 4.47 | 0.000 |
| NM_000696.2        | alcohol dehydrogenase 9 family, member A1 (ALDH9A1) | 89.27±11.55 | 75.57±16.01 | 1.18 | 0.513 |

1The gene expression levels (sample mean ± standard error) shown were median normalized.
2Fold difference of gene expression levels (sample mean) between NASH liver tissues and normal liver controls.
3Two tailed student t test.
do:10.1371/journal.pone.0009570.t005

1Fold difference of gene expression levels (sample mean) between NASH liver tissues and normal liver controls.
Figure 2. Quantitative RT-PCR analysis with NASH livers and NCs. Gene expression levels of (A) ADH1C, (B) ADH4, (C) ADH6, (D) ALDH2, (E) ALDH8A1 and (F) TLR4 were examined by qRT-PCR as described in Methods. The complementary DNAs prepared from NASH livers (n = 6) and NCs (n = 6) were analyzed in duplicate. PCR primer pairs are specified in Table 2. Gene expression levels of each sample were normalized with those of GAPD. Sample means were plotted with error bars indicating the standard errors.

doi:10.1371/journal.pone.0009570.g002
P = 0.002). Real-time PCR analysis with an overlapping but different subgroup of NASH samples indicated that TLR4 gene transcription was not elevated in NASH livers (Figure 2F). Therefore, the small elevation in TLR4 gene transcription observed with microarray analysis may not be a universal phenomenon in NASH liver.

Elevated Protein Expression of ADH1 and ADH4 in NASH Livers

To examine the expression of ADH at protein level, Western blot analyses were performed with the lysates made from NASH liver biopsies (NASH, n = 9; Control, n = 4). As normal healthy liver tissue from adolescent is not available, non-NASH liver biopsies free from steatosis were used as controls. Blots were probed with antibodies specific for ADH1 and ADH4, respectively. Separate blot was also probed for β-actin as loading controls. While all samples had similar signals for actin, NASH patients exhibited higher expression of ADH1 and ADH4 (Figure 3A). Quantitation of the results with NIHimage software indicated that there were significant increases in ADH1 and ADH4 proteins in NASH livers: for ADH1, NASH/normal control = 2.8, P < 0.001; for ADH4, NASH/normal control = 4.1, P < 0.001 (Figure 3B).

Discussion

Liver Specific Genes, Inflammation and Fibrosis Related Genes

Gene transcription of NASH livers was examined by a whole genome DNA microarray and qRT-PCR techniques. Although the sample size in the microarray analysis (NASH, n = 7; NC, n = 4) is relatively small, convincing results were observed with a larger sample size (NASH, n = 6; NC, n = 6) in qRT-PCR analysis. The similar gene expression patterns detected by both techniques testify to the reliability of the techniques and the results. We acknowledge that the clinical information of the normal liver RNA purchased from Admet is limited. However, we are confident that these samples are appropriate to serve as controls, not only because Admet guaranteed that these samples were derived from normal healthy livers intended for transplantation, but also for the following reasons: 1) each of the normal controls had a moderate BMI, therefore they were not likely to have NASH (Table 1); 2) comparison with similar gene transcription datasets of human breast cancer showed that both the normal control RNA and NASH RNA exhibited similar good quality, that is, liver specific genes were highly expressed in both groups of liver tissue (Table 3);
and 3) these normal liver samples showed lower transcription of inflammation and fibrosis related genes as compared to NASH liver samples, in the context of similar gene transcription for housekeeping genes between these two groups (Table 4 and Figure 1).

**Genes Responsible for Alcohol Catabolism**

Alcohol is promptly removed from circulation via three cellular mechanisms mainly found in liver: alcohol dehydrogenases in the cytosol; MEOS (with cytochrome P450 2E1 as the major component) in endoplasmic reticulum and catalase in peroxisomes. All known ADH genes except ADH7, together with cytochrome P450 2E1 and catalase genes, showed elevated transcription in NASH livers. The different behavior of ADH7 from other alcohol oxidizing enzymes is predicted by the fact that ADH7 is not a liver enzyme [17]. The elevated expression for ADH1 and ADH4 at protein level were also observed in NASH livers (NASH, n = 9; NC, n = 4), consistent with the elevated mRNA levels for these genes. The significant elevation of the activity of these enzymes indicated that 1) alcohol concentration was elevated in the circulation and 2) it is a high priority for NASH patients to remove alcohol from the circulation.

All our adolescent patients claimed that they were not regular drinkers of alcoholic beverages. We also were assured by their parents that these adolescent patients had no access to alcoholic beverages. Even, in the event that some of our patients did ingest alcohol, it was certainly not consistent long-term alcohol use. In considering other possible sources of alcohol (aspartame, fruit), we also did a three day food record before any biopsy was performed. We found no significant sources for alcohol.

Where did the alcohol come from? For people who do not have access to alcoholic beverages, circulating alcohol mainly comes from diet and intestinal bacteria. For instance, the concentration of methanol in the human body could increase by an order of magnitude after consumption of fruit [18]. Alcohol production by intestinal bacteria was observed long ago in rodents and humans [19,20]. Studies with obese ob/ob mice indicated that intestinal bacteria are the largest source of circulating alcohol in obese animals [10]. When intestinal bacterial growth was inhibited with neomycin, a 50% decrease of circulating alcohol was observed in obese mice. Based on this observation, Diehl and her colleagues hypothesized that intestinal production of alcohol may contribute to the genesis of non-alcoholic liver diseases [10]. Coincidently, our microarray data provided molecular biological evidence in support of this hypothesis. To pursue this avenue, the immediate future directions are 1) to examine the enzymatic activities of the enzymes related to alcohol catabolism, and 2) to measure the concentrations of circulating alcohol in NASH patients and healthy subjects. If these studies come to the same conclusion as the mRNA data suggest, oral antibiotics, lactobacillus or other means of altering colonic bacteria might be a treatment for NASH.

Our results are also consistent with two interesting discoveries. First, it was observed that cytochrome P450 2E1 is ethanol inducible, with a 4–10 fold increase in liver biopsies of recently drinking subjects [21]. Second, increased P450 2E1 was detected in NASH patients [22].

**Alcohol and Steatosis**

The pathomechanisms of alcohol in liver disease have been intensively studied in alcoholic liver disease. It has long been observed that ethanol stimulates hepatic fatty acid synthesis [23].
The oxidation of alcohol to aldehyde by ADH concomitantly reduces NAD to NADH. The increased NADH promotes fatty acid synthesis and opposes lipid catabolism, leading to fat accumulation in hepatocytes [23,24]. Elevated ADH level as suggested by our microarray data strengthens the connection between alcohol metabolism and steatosis.

Alcohol and Liver Inflammation

One possible mechanism for alcohol induced liver inflammation begins with mucosal injury in the upper gastrointestinal tract induced by alcohol. This leads to increased permeability for macromolecules like LPS endotoxin. The resulting endotoxemia would then activate TLR4 mediated signaling and culminate in the release of pro-inflammatory cytokines [reviewed in [25]]. If the intestinal bacteria could cause elevated production of alcohol, it is conceivable that the NASH patients may suffer from endotoxemia. However, for all the TLR4 related genes examined (TLR4, LBP, CD14, and MD-2), the microarray and real-time PCR analysis did not show significant activation at the mRNA level in NASH patients. Although more convincing conclusion awaits studies of TLR4 signaling at the protein level in NASH patients, our data suggest an emphasis on direct toxicity of alcohol per se.

Szabo and her colleagues reported that alcohol directly suppressed the NF-kB activity in monocytes [26]. Their results are in concert with a previous report that ethanol suppressed TNF activity [27]. However, McClain’s group reported the opposite. They found that peripheral blood mononuclear cells from patients who had alcoholic hepatitis have spontaneous TNF production and enhanced LPS-stimulated TNF production [28]. Their finding was confirmed with an in vivo experiment using rats chronically fed alcohol [29]. Work in Nagy’s lab further revealed that ERK1/2 and Egr-1 are important mediators in elevated TNF-α production after chronic ethanol exposure [30,31]. The reality of the ethanol effect on TNF-α production was made clear by Kolls’ group. In a time-series alcohol experiment, they demonstrated that acute ethanol exposure suppressed TNF production, while long-term treatment significantly up-regulated TNF production [32]. More importantly, the increase in TNF production was associated with increased generation of reactive oxygen species (ROS).

Therefore, ROS could be the important mediator between alcohol and TNF. Alcohol is known to induce cytochrome P450, mainly CYP2E1 [33]. Metabolism by CYP2E1 generates superoxide and other free radicals collectively known as ROS. There are two possible mechanisms for ROS to induce TNF production. Firstly, ROS could serve as signaling molecules to activate NF-kB, leading to elevated transcription of TNF-α [34]; Secondly, ROS could activate TNF-α converting enzyme, the enzyme responsible for the processing of the transmembrane TNF-α precursor [35].

In summary, the gene expression studies of NASH livers revealed elevated transcription of enzymes in ALL the alcohol metabolism pathways: ADH1 pathway, catalase pathway and the MEOS pathway. Elevated expression of ADH1 and ADH4 at protein level were also observed in NASH livers. These results support a central role for alcohol in the development of NASH in obese patients, as summarized in Figure 4 and for the first time, provide molecular evidence in support of Diehl et al.’s hypothesis that alcohol is an important mediator for the development of non-alcoholic fatty liver diseases [10]. Our findings suggest a mechanism that offers a single explanation for the similar histological findings in alcoholic liver disease and NASH [3]. Our findings might provide a basis for studies on the prevention and treatment of NASH.

Acknowledgments

The authors thank Chaoyan Liu, Cuiling Shu and Giam Visentin for their excellent technical assistance in RNA preparation and primer design for real-time quantitative PCR.

Author Contributions

Conceived and designed the experiments: SSB RDB WL NN LZ. Performed the experiments: SSB RDB WL NN LZ. Analyzed the data: SSB RDB WL NN LZ. Wrote the paper: SSB RDB WL NN LZ.

References

1. Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434–438.
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. (2004) Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40: 1387–1395.
3. Day CP, James OF (1996) Steatohepatitis: a tale of two “hins”? Gastroenterology 114: 842–845.
4. Sanyal AJ, Campbell-Sargent C, Minniali F, Rizzo WB, Contos MJ, et al. (2001) Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120: 1183–1192.
5. Donnelly KL, Smith CI, Schwarzenberg SJ, Jesurun J, Boldt MD, et al. (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343–1351.
6. Gervois P, Fruchart JC, Staels B (2007) Drug Insight: mechanisms of action and characterization of a class IV human alcohol dehydrogenase gene (ADH7). FEBS Lett 531: 411–415.
7. Szabo G, Velayudham A, Romics L, Jr., Mandrekar P (2005) Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 29: 1408–1458.
8. Kawaratani H, Tsujimoto T, Kitazawa T, Kitade M, Yoshiji H, et al. (2008) Innate immune activity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J Gastroenterol 14: 6655–6661.
9. Yokoyama S, Matsuo Y, Ramachotham R, Yokoyama R (1994) Molecular characterization of a class IV human alcohol dehydrogenase gene (ADH7). FEBS Lett 351: 411–415.
10. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1131–1321.
11. Rogen S, Skalicky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365–386.
12. Yokoyama S, Matsuo Y, Ramachotham R, Yokoyama R (1994) Molecular characterization of a class IV human alcohol dehydrogenase gene (ADH7). FEBS Lett 351: 411–415.
22. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C (1998) Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27: 128–133.
23. Lieber CS, Schmid R (1961) The effect of ethanol on fatty acid metabolism; stimulation of hepatic fatty acid synthesis in vitro. J Clin Invest 40: 394–399.
24. Galli A, Price D, Grubb D (1999) High-level expression of rat class I alcohol dehydrogenase is sufficient for ethanol-induced fat accumulation in transduced HeLa cells. Hepatology 29: 1164–1170.
25. Bode C, Bode JC (2005) Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol? Alcohol Clin Exp Res 29: 166S–171S.
26. Mandrekar P, Catalano D, Szabo G (1999) Inhibition of lipopolysaccharide-mediated NFkappaB activation by ethanol in human monocytes. Int Immunol 11: 1781–1790.
27. Nelson S, Bagby G, Summer WR (1989) Alcohol suppresses lipopolysaccharide-induced tumor necrosis factor activity in serum and lung. Life Sci 44: 673–676.
28. McClain CJ, Cohen DA (1989) Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 9: 349–351.
29. Honchel R, Ray MB, Marsano L, Cohen D, Lee E, et al. (1992) Tumor necrosis factor in alcohol enhanced endotoxin liver injury. Alcohol Clin Exp Res 16: 665–669.
30. Kishore R, Hill JR, McMullen MR, Frenkel J, Nagy LE (2002) ERK1/2 and Egr-1 contribute to increased TNF-alpha production in rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol 282: G6–15.
31. Shi L, Kishore R, McMullen MR, Nagy LE (2002) Chronic ethanol increases lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages: contribution to enhanced tumor necrosis factor alpha production. J Biol Chem 277: 14777–14785.
32. Zhang Z, Bagby GJ, Stoltz D, Oliver P, Schwarzenberger PO, et al. (2001) Prolonged ethanol treatment enhances lipopolysaccharide/phorbol myristate acetate-induced tumor necrosis factor-alpha production in human monocytic cells. Alcohol Clin Exp Res 25: 444–449.
33. Lieber CS (1999) Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968–1998) a review. Alcohol Clin Exp Res 23: 991–1007.
34. Schreck R, Rieber P, Baeuerle PA (1993) Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 10: 2247–2256.
35. Zhang Z, Kolls JK, Oliver P, Good D, Schwarzenberger PO, et al. (2000) Activation of tumor necrosis factor-alpha converting enzyme-mediated ectodomain shedding by nitric oxide. J Biol Chem 275: 15839–15844.